Steroid minimization immunosuppression protocol using basiliximab in adult living donor liver transplantation for hepatitis C virus-related cirrhosis

摘要: Aim Recent randomized trials have failed to prove the benefit of steroid-free immunosuppression in liver transplantation for hepatitis C virus (HCV)-related cirrhosis. Furthermore, there is a lack data on use basiliximab living donor (LDLT). This pilot study evaluated safety and efficacy steroid minimization protocol using compared with standard immunosuppression. Methods A single center, prospective cohort analysis was conducted compare two regimens adult recipients who underwent LDLT HCV since 2004: calcineurin inhibitor/mizoribine/basiliximab (the St− group) inhibitor/mizoribine/steroid St+ group). Study end-points were rejection rates, recurrent HCV, patient survival other adverse events up 2 years after transplantation. Results A total 27 consecutive patients enrolled. Transplantation characteristics similar between groups (14 13 St+) except ABO incompatible cases being more common group. Rejection survival, fibrosis stage new-onset diabetes mellitus at comparable groups. incompatibility did not affect short- long-term outcomes. Nine seven interferon ribavirin therapy sustained virological response rate 33% 29%, respectively. Conclusion A safe affords equivalent rates immunosuppression. However, no significant differences are observed respect metabolic complications.